Renal Artery Stenosis November 12, 2009 Lance D. Dworkin, M.D., and Christopher J. Cooper, M.D. Clinical Practice 2010 년 3 월 23 일 화요일 신장내과 R4 이완수.

Slides:



Advertisements
Similar presentations
Preventing Strokes One at a Time Acute Interventions and Management 2009.
Advertisements

RENAL SYMPATHETIC DENERVATION Anxiolytic for nervous kidneys???
Harvard Medical School Duane S. Pinto, M.D. Director Peripheral Angiographic Core Laboratory, TIMI Data Coordinating Center Director, Cardiology Fellowship.
National Institute for Health and Clinical Excellence.
Stenting and Medical Therapy for Atherosclerotic Renal-Artery Stenosis NEJM, Jan 2014, M Graham-Brown 28/05/14.
Zehra Eren, M.D.. explain hypertansion and renal disease interaction, describe renovascular diseases describe diagnostic evaluation explan therapy in.
Management of Hypertension according to JNC 7 BY SANDAR KYI, MD.
Only You Can Prevent CVD Matthew Johnson, MD. What can we do to prevent CVD?
Source: Site Name and Year IHS Diabetes Audit Diabetes Health Status Report ______Site Name_________ Health Outcomes and Care Given to Patients with Diabetes.
1 What is… ? Disparities Among Women in Acute Cardiac Care Frances Canet, MD Cath Conference Thursday, May 26, 2011.
Assessment, Targets, Thresholds and Treatment Bryan Williams NICE clinical guideline 127.
Arthur Stillman, M.D., Ph.D., PI Pamela Woodard, M.D., Study Co-chair Randomized Evaluation of Patients with Stable Angina Comparing Utilization of Diagnostic.
Management of Renal Artery Stenosis Kent MacKenzie, MD Division of Vascular Surgery McGill University Montreal, Quebec.
HOME AND AMBULATORY BLOOD PRESSURE MONITORING
Systemic Hypertension. Systemic blood pressure measures 140/90 mm Hg or higher on at least two occasions a minimum of 1 to 2 weeks apart.
One stage coronary and peripheral intervention Pawel Buszman, MD, American Heart of Poland, Ustron Silesian Medical School, Katowice.
Rashad MAHMUDOV Central Hospital of Oilworkers, Baku-Azerbaijan
Renovascular Disease Daniel Shoskes MD, MSc, FRCSC Professor of Surgery/Urology Glickman Urological and Kidney Institute Cleveland Clinic.
Management of Chronic Stable Angina AIMGP Seminar Series Mirek Otremba 2007.
Atherosclerosis Part 1 Atherosclerosis The general term for hardening of the arteries The most prevalent form of atherosclerosis is characterized by the.
Endarterectomy versus Stenting in Patients with Symptomatic Severe Carotid Stenosis Dr. Quan, Dr. Mirhashemi, Dr. Chiang N Engl J Med 2006; 355:
Unstable angina and arterial hypertension Leszek Kinasz, MD American Heart of Poland Ustron, Poland.
Philip A Kalra Lead Nephrologist for ASTRAL, Hope Hospital, Salford, UK, On behalf of the ASTRAL TMC and collaborators UK MULTI-CENTRE TRIAL IN ATHEROSCLEROTIC.
CARDIOVASCULAR CARE of the OUTPATIENT Diane M. Enzweiler, MSN, ANP-BC St. Elizabeth Physicians: Heart and Vascular.
Medical Progress: Heart Failure. Primary Targets of Treatment in Heart Failure. Treatment options for patients with heart failure affect the pathophysiological.
Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.
Randomized Trial of Ea rly S urgery Versus Conventional Treatment for Infective E ndocarditis (EASE) Duk-Hyun Kang, MD, PhD on behalf of The EASE Trial.
Case Report and Lit Review: Reduction of Proteinuria in Diabetic Nephropathy with Spironolactone Harry W. Floyd, M.D. Family Medicine Kingstree, South.
Radka Adlová Arterial hypertension and preventive cardiology.
HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.
Atherosclerotic Disease of the Carotid Artery Atherosclerosis is a degenerative disease of the arteries resulting in plaques consisting of necrotic cells,
ALLHAT Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA 2002;288:
Although in more than 90% of patients with high blood pressure no underlying causes could be identified, up to 10% of hypertensives have a secondary.
ACC/AHA 2006 guidelines on the management of PAD.
Hypertension Family Medicine Specialist CME October 15-17, 2012 Pakse.
Hypertension and renovascular hypertension BY Dr. Hayam Hebah Associate professor of Internal Medicine AL Maarefa College.
Renovascular hypertension Dr Saad Al Shohaib KAUH.
Late Open Artery Hypothesis Jason S. Finkelstein, M.D. Tulane University Medical Center 2/24/03.
بسم الله الرحمن الرحيم. RENAL ARTERY STENOSIS  Lecture by:  Dr. Zaidan Jayed Zaidan.
BY Dr. Hayam Hebah Associate professor of Internal Medicine AL Maarefa College.
MACROVASCULAR COMPLICATIONS, DYSLIPIDEMIA and HYPERTENSION 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada.
Treatment of Hypertension in Adults With Diabetes DR AMAL HARFOUSH.
Relationship between coronary and renal artery disease and associated risk factors in hypertensive and diabetic patients undergoing coronary angiography.
KIDNEY & HYPERTENTION 1 Dr. Ruba Nashawati. Kidney Hypertension 2.
A Randomized Trial of Intensive versus Standard Blood-Pressure Control The SPRINT Research Group* November 9, /NEJMoa R2 이성곤 /pf. 우종신.
The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Left Ventricular Filling Pressure by Doppler Echocardiography in Patients With End-Stage Renal Disease Angela Y-M Wang, Mei Wang, Christopher W-K Lam,
Faramarz Amiri MD IUMS.  Severe carotid disease (defined as >80%) 8–12%  Severe carotid disease (>70%) in those with three vessel or left main coronary.
Date of download: 7/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Uncertain Value of Renal Artery Interventions:
Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: ACCF/ASNC/ACR/AHA/ASE/SCCT/SCMR/SNM 2009 Appropriate.
신장내과 R4 강혜란 Cardiorenal syndrome (CRS).  Patients with heart failure (HF) who have a reduced GFR -> Mortality ↑  Patients with chronic kidney disease.
Review Renovascular hypertension Department of nephrology R4 최소영.
Renal vascular disease
Management of Hypertension according to JNC 7
Renovascular Disease Daniel Shoskes MD, MSc, FRCSC
Renovascular Hypertension
Renal Artery Angioplasty and Stenting: Optimal Patient Selection
Angiotensin converting enzyme inhibitors / angiotensin receptor blockers and contrast induced nephropathy in patients receiving cardiac catheterization:
Hypertension and renovascular hypertension
TUCOM Internal Medicine 4th class
Multi Modality Approach to Diagnosis of Ischemia in Post CABG Cases
Hypertension JNC VIII Guidelines.
Renal Artery Angioplasty and Stenting
Patient Selection Indications for Renal Intervention
The Anglo Scandinavian Cardiac Outcomes Trial
Giuseppe Biondi Zoccai, MD
Hypertension evaluation
Table of Contents Why Do We Treat Hypertension? Recommendation 5
Cardiovascular Epidemiology and Epidemiological Modelling
Presentation transcript:

Renal Artery Stenosis November 12, 2009 Lance D. Dworkin, M.D., and Christopher J. Cooper, M.D. Clinical Practice 2010 년 3 월 23 일 화요일 신장내과 R4 이완수

Case Vignette Age/Sex –73/male Chief compliant –shortness of breath  ER visit Personal History –former smoker Past History –Hypertension –Dyslipidemia Vital sign BP 160/75 mmHg HR 60 beats/min RR 24 breaths/min Physical Examination Chest auscultation - diffuse rales Pitting edema (1+) Lab. Serum Creatinine 1.4 mg/dL (eGFR 52ml/min) Urinalysis protein 1+

Case Vignette Condition improves after treatment (IV diuretics) But, systolic BP remains elevated (170 mmHg) Magnetic resonance angiography (MRA) –diseased aorta –Lt. renal artery (ostial lesion)  High grade “atherosclerotic stenosis” –Rt. renal artery  normal How should he be further evaluated and treated? Renal artery stenosis (Lt.)

Outline The Clinical Problem Strategies and Evidence –Evaluation –Treatment Options Medical Therapy Surgical Therapy Angioplasty and Stenting Areas of Uncertainty Guidelines Conclusions and Recommendations

The Clinical Problem “Renal-artery stenosis” Definition –narrowing of one or both renal arteries or their branches. Cause –1. atherosclerosis (most common, 90%) –2. fibromuscular dysplasia (Less frequently) –3. other causes (rare) Vasculitis (Takayasu’s arteritis) Dissection of the renal artery Thromboembolic disease Renal artery aneurysm Renal artery coarctation Extrinsic compression Radiation injury

Characteristics of Atherosclerotic Renal-Artery Stenosis and Fibromuscular Dysplasia balloon angioplastycontroversialEffective Tx.?

Prevalence –atherosclerotic renal artery stenosis in CKD – 0.5~5.5% –true frequency maybe higher ( ∵ often asymptomatic) Anatomical progression –occur in more than one third of patients –But, one study 5 yrs F/U, “Stenosis”  “Occlusion “ only 3~15% patients treated medically conducted before statin therapy was available Medical treatment is important!!

Pathogenesis RAS : renal artery stenosis RBF : renal blood flow

Other vascular event? –Renal-artery stenosis (  HTN, CKD)  increased risk for vascular events –Explanation?? Uncertain concomitant atherosclerosis in other vascular beds activation of the renin–angiotensin–aldosterone activation of the sympathetic nervous systems associated renal insufficiency all these factors chronic kidney disease (25%, vs 2%) coronary artery disease (67% vs 25%) stroke (37% vs 12%) peripheral vascular disease (56% vs 13%)

Classic clinical clues (renal artery stenosis) 1. onset of stage 2 hypertension (BP >160/100mmHg) after 50yrs old 2. family history of hypertension (-) 3. hypertension associated with renal insufficiency (Esp, RAAS inhibition agent  renal fuction wosens) 4. hypertension with repeated hospital admissions heart failure drug-resistant hypertension (treatment c three drug of different class  BP control fail) Strategies and Evidence

Diagnostic Imaging Tests for Renal-Artery Stenosis Once renal-artery stenosis is suspected?? confirmation of the diagnosis??  imaging!! ∵ biochemical tests (plasma renin concentrations)  specificity ↓

Duplex Ultrasonography in a Patient with Renal-Artery Stenosis Excellent tool non-invasive no apparent side effects Measurement “renal-artery velocity”  functional assessment of the “severity of stenosis” higher velocity  greater pressure differential across the stenosis Limitation abdominal obesity bowel gas technically demanding (not available at all centers)

Magnetic Resonance Angiography Computed Tomographic Angiography High-resolution multislice detector devices Elegant images of the renal arteries and the abdominal aorta Limitation  may affect image quality –equipment –technique –reconstruction of the images –patient-related factors presence of calcium presence of stents ability to hold one's breath during imaging Caution) –CKD patients : toxicity of the contrast medium nephrogenic systemic fibrosis is associated with gadolinium nephropathy is associated with iodinated contrast dye

Rt. renal aterty (arrow) 70% ostial stenosis systolic pressure gradient of 28mmHg Lt. renal artery (arrowhead) 40% ostial stenosis pressure gradient of 13mmHg Magnetic Resonance Angiography of the Renal Arteries Showing Severe Bilateral Stenosis

Digital subtraction angiography Best image quality, anatomy information use of small-diameter catheters and minimal amounts of contrast material  reduce the risk of vascular complications and contrast nephropathy Limitation –invasive –only in experienced centers –contrast nephropathy in CKD –atheroembolic event –vascular complication at punture site –Radation exposure

degree of atherosclerosis of the aorta size of the kidney extent of poststenotic dilatation rapidity of the appearance and washout of contrast material Useful in diagnosis of Renal artery stenosis “Functional significance” of the lesion ? Predict the “response to revascularzation” ? No conclusive test nuclear scintigraphy renin sampling from the renal veins pressure gradients across stenoses Kidney (supplied by an occluded renal artey) is viable? Contributing to hypertension ? Stenosis is affecting intrarenal pressure?

Treatment Options Medical Therapy Surgical Therapy Angioplasty and Stenting  improved survival improved BP control less impairment of renal function

Medical Therapy Cornerstone of treatment for renal-artery stenosis Recommendations –Multidrug regimens for BP control –RAAS inhibitor is recommended in most patients (Renin–angiotensin–aldosterone system is often activated in patients with renal-artery stenosis) –alpha-blocker or beta-blocker –long-acting CCB –diuretics Caution) “Bilateral severe stenosis“ Use of “RAAS inhibitor”  ARF High-grade stenosis in one kidney Advanced chronic kidney disease  probability of this complication appears to be low in most cases, it is reversible with the discontinuation of treatment

Medical Therapy Recent data –ACE inhibitor  reduced risk of death –Statin  reduction in the severity of renal artery stenosis –Statin c stenting  improve survival –Statin, antiplatelet therapy  benefit in patient with atherosclerotic disease

Surgical Therapy Surgical revascularization –durable relief of renal-artery stenosis –improves BP control and kidney function Safety –recent data have indicated a 10% in-hospital mortality after this procedure among Medicare patients “balloon angioplasty” vs “surgery” –58 patients with renal-artery stenosis, randomized trial –resulted in similar rates of cure or improvement in HTN, renal function “nonsurgical revascularization”  first-line approach (if an intervention is planned)

Angioplasty and Stenting “Fibromuscular dysplasia” –balloon angioplasty remains the preferred form  many patients are able to discontinue all antihypertensive medications –But, medical therapy alone may be appropriate in patients with well-controlled hypertension “Atherosclerotic renal artery stenosis” –balloon angioplasty Less effective Restenosis 71%↑ 3 multicenter trials, without stenting –1 yr follow-up, no significant improvement in BP But, controversial

Angioplasty and Stenting Predictors of a favorable outcome of angioplasty –40 years ↓ at diagnosis –duration of hypertension <5 yrs –systolic BP <160 mmHg

Angioplasty and Stenting Stents –limit elastic recoil –restenosis-free patency ↑ (compared with angioplasty alone) –BP control ↑after stenting

Angioplasty and Stenting Recent trials –1. comparing stenting plus medical therapy with medical therapy alone preservation of renal function no significant benefits with the addition of stenting –2. Angioplasty and Stenting for Renal Artery Lesions (ASTRAL) stent revascularization in addition to medical therapy vs medical therapy alone renal function, mean systolic blood pressure, in rates of renal or cardiovascular events or death no significant difference between the study groups at the 5yrs follow-up

Angioplasty and Stenting –3. Stenting in Renal Dysfunction Caused by Atherosclerotic Renal Artery (STAR) trial prevention of loss of kidney function serious procedure-related complications stenting plus medical therapy vs medical therapy alone did not show a benefit

Angioplasty and Stenting Revascularization –renin–angiotensin–aldosterone system ↓ –sympathetic nervous system ↓ –possible cardiovascular benefits “pharmacologic therapy”?? directed at these pathways  may have similar benefits  improved survival improved BP control less impairment of renal function

Areas of Uncertainty Response to revascularization?  no method reliably predicts Optimal treatment strategy? “Angioplasty and Stenting” vs “medical therapy alone”  remains unclear Data are lacking –randomized clinical trials comparing the effects of various medical regimens Available data from randomized trials –not shown a benefit of “revascularization plus medical therapy” with respect to blood-pressure control and renal function –But, these trials had methodologic limitations, were not powered for the assessment of cardiovascular outcomes, and did not include quality-of-life assessments

Previous algorithm

Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL) study –large, multicenter, randomized, controlled trial –funded by the National Institutes of Health –scheduled to be completed in 2011 –medical therapy plus stent revascularization vs medical therapy alone –end point : cardiovascular and renal events –Pending the results of the study best treatment for renal-artery stenosis ? whether to evaluate ?  remain uncertain

Guidelines American College of Cardiology–American Heart Association 2005 guidelines (for the care of patients with peripheral-artery disease, including renal-artery stenosis) Revascularization recommendations –class I evidence (i.e., general agreement on usefulness) recurrent congestive heart failure pulmonary edema –class IIa evidence (i.e., conflicting opinions, but with the preponderance of evidence favoring usefulness) global renal ischemia progressive chronic kidney disease unstable angina hypertension that is worsening resistant to medical therapy malignant unexplained unilateral small kidney cannot tolerate antihypertensive medication

Conclusions and Recommendations A diagnosis of renal-artery stenosis should be considered in any patient with a history of severe or resistant hypertension, hypertension that is associated with renal insufficiency, or disease in other vascular beds. Clinical Finding Associated with Renal Artery Stenosis Hypertension Abrupt onset of hypertension (age<40)  fibromuscular dysplasia Abrupt onset of hypertension (age>50)  renal artery stenosis Accelerated or malignant hypertension Refractory hypertension (not responsive to therapy c 3≥drugs) Renal abnormalities Unexplained azotemia  renal artery stenosis Azotemia induced by treatment with an angiotensin converting enzyme inhibitor Unilateral small kidney Unexplained hypokalemia Other findings Abdominal bruit, flank bruit, or both Severe retinopathy Carotid, coronary, or peripheral vascular disease Unexplained congestive heart failure or acute pulmonary edema

Conclusions and Recommendations Initial examination  measurement of kidney function and a lipid profile Anatomical diagnosis –duplex ultrasonography –CTA or MRA (if high-quality duplex imaging is not available) Therapy –intensive medical therapy –tight BP control with a blocker of the RAAS (serum creatinine and potassium should be closely monitored) –administration of an antiplatelet agent and a statin –Treatment of diabetes and chronic kidney disease Revascularization in the treatment of atherosclerotic renal-artery stenosis ?  controversial